US Tresiba resubmission 'ahead of schedule'
This article was originally published in Scrip
Executive Summary
Novo Nordisk, the world's biggest insulin maker, reported second quarter results mostly in line with expectations. However, the real news coming out of the results presentation was that clinical data for its new long-acting insulin Tresiba (insulin degludec) might be available six months earlier than previously thought.